Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ark Biosciences In-Licenses Pulmonary Fibrosis Candidate from Roche

publication date: Sep 3, 2018

Ark Biosciences, a Shanghai-Suzhou clinical stage biotech, has in-licensed global rights to a treatment for idiopathic pulmonary fibrosis (IPF) from Roche. Ark believes the candidate, which has completed its first-in--human trial, has the potential to become standard-of-care. Ark will be responsible for milestone and royalty payments, and Roche will retain certain preferential rights, though further details were not disclosed. Ark has its own innovative drug R&D operations for respiratory and infectious disease, while also in-licensing promising candidates. More details....

Stock Symbol: (SWX: ROG)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital